Ferrata Storti Foundation

SHERPA: Unknown

People

  1. Levine
    Levine
  2. Tallman
    Tallman
  3. Zelenetz
    Zelenetz
  4. Mauro
    Mauro
  5. Stein
    Stein
  6. Abdel-Wahab
    Abdel-Wahab
  7. Dogan
    Dogan
  8. Horwitz
    Horwitz
  9. Perales
    Perales
  10. Salles
    Salles

Groups

  1. Department of Medicine (294)
  2. Hematologic Malignancies, Division of (293)
  3. Center for Hematologic Malignancies (269)
  4. Adult Leukemia (106)
  5. Lymphoma (73)
  6. GSK Faculty (70)
  7. Executive Committee, Center for Hematologic Malignancies (60)
  8. Hematologic Malignancies Research (45)
  9. Sloan Kettering Institute Postdocs (43)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (41)
Search Within
Formats
  1. Meeting Abstract (178)
  2. Journal Article (122)
  3. Research Letter (26)
  4. Editorial (15)
  5. Review (11)
  6. Correspondence (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (294)
  2. Hematologic Malignancies, Division of (293)
  3. Center for Hematologic Malignancies (269)
  4. Adult Leukemia (106)
  5. Lymphoma (73)
  6. GSK Faculty (70)

More Groups

People
  1. Carl Landgren (25)
  2. Andrew Zelenetz (24)
  3. Martin Tallman (24)
  4. Ross Levine (24)
  5. Michael Mauro (21)
  6. Anas Younes (16)

More People

Years
  1. 2025 (14)
  2. 2024 (23)
  3. 2023 (17)
  4. 2022 (20)
  5. 2021 (13)
  6. 2020 (18)

More Years

Publications
  1. Haematologica (350)
  2. Haematologica Meeting Reports (4)

Results (354)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Enasidenib (AG-221) in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase 1 dose-escalation and expansion study
    Meeting Abstract

    Stein, E. M.; DiNardo, C. D.; Pollyea, D. A.; Fathi, A. T.; Roboz, G. J.; Altman, J. K.; Stone, R. M.; Flinn, I. W.; Kantarjian, H. M.; Collins, R.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Patients with light chain amyloidosis treated with NEOD001 achieve rapid organ responses that are independent of previous plasma cell-directed therapies
    Meeting Abstract

    Gertz, M. A.; Comenzo, R. L.; Landau, H.; Sanchorawala, V.; Weiss, B. M.; Zonder, J. A.; Walling, J.; Kinney, G. G.; Koller, M.; Schenk, D. B.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Identification of aberrantly spliced genes and deregulated pathways/gene ontology themes in myelodysplastic syndrome patients with splicing factor gene mutations
    Meeting Abstract

    Pellagatti, A.; Steeples, V.; Sharma, E.; Repapi, E.; Radujkovic, A.; Horn, P.; Armstrong, R. N.; Dolatshad, H.; Roy, S.; Lockstone, H.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL
    Meeting Abstract

    Park, J.; Riviere, I.; Wang, X.; Senechal, B.; Wang, Y.; Santomasso, B.; Sadelain, M.; Brentjens, R.
    Haematologica (2017)

    Fulltext@MSK | Save
  • Vadastuximab talirine plus hypomethylating agents: A well-tolerated regimen with high remission rate in frontline older patients with acute myeloid leukemia
    Meeting Abstract

    Ravandi, F.; Stein, A.; Erba, H.; Lancet, J.; Stein, E.; Faderl, S.; Walter, R.; Advani, A.; DeAngelo, D.; Kovacsovics, T.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • The effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemia
    Journal Article

    Brunstein, C.; Zhang, M. J.; Barker, J.; St. Martin, A.; Bashey, A.; De Lima, M.; Dehn, J.; Hematti, P.; Perales, M. A.; Rocha, V.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
    Journal Article

    Engelhardt, M.; Domm, A. S.; Dold, S. M.; Ihorst, G.; Reinhardt, H.; Zober, A.; Hieke, S.; Baayen, C.; Müller, S. J.; Einsele, H.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Nivolumab re-treatment in patients with relapsed/refractory Hodgkin lymphoma: Safety and efficacy outcomes from a phase 1 clinical trial
    Meeting Abstract

    Ansell, S.; Armand, P.; Timmerman, J.; Shipp, M.; Popa McKiver, M.; Zhu, L.; Lesokhin, A. M.
    Haematologica (2016)

    Fulltext@MSK | Save
  • Brentuximab vedotin after autologous stem cell transplant yields the strongest benefit in Hodgkin lymphoma patients with ≥2 risk factors: Results of a multivariate analysis
    Meeting Abstract

    Moskowitz, C.; Sweetenham, J.; Chen, A.; Ayala, E.; Masszi, T.; Holowiecki, J.; Stiff, P.; Carella, A.; Viviani, S.; Bachanova, V.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Results of US Intergroup trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for non-bulky stage I and II Hodgkin lymphoma (CALGB/Alliance 50604)
    Meeting Abstract

    Straus, D.; Pitcher, B.; Kostakoglu, L.; Grecula, J. C.; Hsi, E. D.; Schöder, H.; Jung, S. H.; Popplewell, L.; Chang, J. E.; Moskowitz, C.; more...
    Haematologica (2016)

    Fulltext@MSK | Save

    • Ferrata Storti Foundation – authorized name for: